FDA Approves New Drug For Early Treatment Of Alzheimer’s

  • The U.S. Food and Drug Administration on Friday approved a new drug to treat Alzheimer’s disease.
  • Testing reportedly showed considerable success in helping patients with the debilitating condition.
  • The FDA said in a press release that it had approved the drug Leqembi for Alzheimer’s patients. The drug is “the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease,” the agency said.
  • Testing of the drug reportedly showed it having “a statistically significant reduction in brain amyloid plaque,” one of the chief signs of Alzheimer’s progression.